University of Kentucky Research Foundation

Alza Corporation

Interx Research Corporation

New Millennium Pharmaceutical Research, Inc.

Other

Theramax Inc.

Anwar A Hussain

Takeru Higuchi

Lewis W Dittert

John W Shell

Nicolae S Bodor

Kenneth B Sloan

Rima Bawarshi

Shinichiro Hirai

Bassam Tashtoush

Ashraf Traboulsi

Harry B Kostenbauder

James E Truelove

Abdulghani A Houdi

Abeer M Al-Ghananeem

Thomas S Foster

Masahiro Nakano

Ali M Qaisi

This invention provides a method of rapidly and reliably delivering codeine, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route to produce rapid onset of beneficial effects in the treatment of pain or cough. The present invention further provides pharmaceutical compositions comprising codeine, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms, with and without other analgesic and/or antitussive compounds.

Intranasal codeine for the rapid suppression of cough and rapid relief of pain

The present invention provides novel water soluble testosterone analogs. These testosterone analogs are suitable for intranasal administration to patients requiring increased plasma testosterone levels. The present invention also provides pharmaceutical compositions containing the testosterone analogs of the present invention. The present invention further provides a method of increasing plasma testosterone levels in patients in need of such treatment comprising the intranasal administration of the water-soluble testosterone analogs and pharmaceutical compositions of the present invention.

Water soluble amine esters of testosterone for intranasal administration

The present invention is directed to a method for enhancing the delivery of delta-9-tetrahydrocannabinol (&ldquo;THC&rdquo;) to the brain of a mammal in need of treatment with this drug, by administering water-soluble prodrugs of THC intranasally.

Method for enhancement of delivery of THC by the administration of its prodrugs via the nasal route

This invention provides a method of rapidly and reliably delivering folic acid, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route to produce rapid onset of beneficial effects in the treatment or prevention of Alzheimer's Disease and stroke. The present invention further provides intranasal pharmaceutical compositions comprising folic acid, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms, with and without other anti-Alzheimer's or anti-stroke compounds.

Brain delivery of folic acid for the prevention of alzheimer's disease and stroke

This invention provides a method of rapidly and reliably delivering sildenafil, or derivatives thereof, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route so as to produce virtually instantaneous onset of beneficial effects in the treatment of erectile dysfunction. The present invention further provides pharmaceutical compositions comprising sildenafil, or derivatives thereof, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms, with and without apomorphine.

Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction

This invention provides to a method for enhancement of delivery of bupropion by administration via the nasal route, and methods of treatment comprising intranasal administration of bupropion. The present invention further provides pharmaceutical compositions comprising bupropion and/or pharmaceutically acceptable salts thereof.

Method for enhanced brain delivery of bupropion

The present invention relates to N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters, and their use as agents for water disinfection and as mild oxidizing agents for the radiolabeling of oxidation-sensitive biomolecules.

Derivatives of N-chloro-N-methyl glucamine and N-chloro-N-methyl

N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters as

A kit and method of non-destructively radiolabelling a biomolecule substrate by halogenation, including the steps of: a) reacting a secondary amine with a chlorinating agent to produce an N-chloro secondary amine, (b) reacting the N-chloro secondary amine with a salt of a radiolabelled halogen to produce a radiolabelled halogenating agent, (c) reacting a solution of the biomolecule substrate with the radiolabelled halogenating agent, and (d) recovering a radiohalogenated biomolecule from the reaction of step (c). The kit and method allow for more complete iodination with a lessening of side reactions such as decomposition of the biomolecule substrate to be labelled.

Non-destructive method for radiolabelling biomolecules by halogenation

The invention relates to a novel method of administering aspirin to achieve improved delivery thereof. The invention further relates to novel dosage forms of neutralized aspirin adapted for nasal administration, such as solutions, suspensions, gels and ointments. These dosage forms find utility in the treatment of conditions known to respond to the administration of aspirin, particularly in the treatment of migraine and in the mitigation of cardiovascular damage resulting from heart attack.

Novel method of administering aspirin and dosage forms containing same

The invention provides a novel method of administering narcotic antagonists, narcotic analgesics and related compounds, and novel dosage forms containing those compounds which are adapted for nasal administration. The nasal dosage forms disclosed include solutions, suspensions, gels and ointments. Especially preferred compounds which can be advantageously administered in accordance with the invention include naloxone, naltrexone, nalbuphine, levorphanol, buprenorphine, butorphanol, .DELTA..sup.9 -tetrahydrocannabinol (THC), cannabidiol (CBD) and levonantradol.

Method of administering narcotic antagonists and analgesics and novel

The invention provides a novel method of administering selected known adrenergic .beta.-receptor blocking agents, such as dichloroisoproterenol, pronethalol, sotalol and alprenolol, which are of use in the treatment of angina pectoris, arrhythmias, hypertension and other cardiac conditions, and migraine. The invention further provides novel dosage forms of those .beta.-blockers which are adapted for nasal administration and which include solutions, suspensions, gels and ointments.

Novel method of administering .beta.-blockers and novel dosage forms

The invention relates to a novel method of administering propranolol, a known .beta.-adrenergic blocking agent widely used in the treatment of angina pectoris, arrhythmias, hypertension and other cardiac conditions, and migraine. The invention further relates to novel dosage forms of propranolol which are adapted for nasal administration and which include solutions, suspensions, gels and ointments.

Nasal dosage forms of propranol

The invention relates to a novel method of administering the natural female sex hormones, 17 .beta.-estradiol and progesterone, to achieve enhanced bioavailability thereof. The invention further relates to novel dosage forms of 17 .beta.-estradiol and/or progesterone which are adapted for nasal administration, such as solutions, suspensions, gels and ointments. The dosage forms containing a combination of 17 .beta.-estradiol and progesterone are particularly useful as contraceptives, while the dosage forms containing only one of the hormonal components find utility in the treatment of conditions such as menopause, menstrual disorders, etc., which are known to respond to administration of a natural or synthetic female hormone.

Nasal dosage forms containing natural female sex hormones

The invention relates to a novel method of administering the natural female sex hormones, 17 .beta.- estradiol and progesterone, to achieve enhanced bioavailability thereof. The invention further relates to novel dosage forms of 17 .beta.- estradiol and/or progesterone which are adapted for nasal administration, such as solutions, suspensions, gels and ointments. The dosage forms containing a combination of 17 .beta.-estradiol and progesterone are particularly useful as contraceptives, while the dosage forms containing only one of the hormonal components find utility in the treatment of conditions such as menopause, menstrual disorders, etc., which are known to respond to administration of a natural or synthetic female hormone.

Growing community of inventors

Lexington, KY, United States of America

Anwar A Hussain